Abstract On July 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab
(Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials …

Aging is a major risk factor for numerous chronic diseases. Vaccination offers a promising
strategy to combat these age-related diseases by targeting specific antigens and inducing …

A broad range of data identify Ca2+-permeable amyloid pores as the most neurotoxic
species of Alzheimer's β-amyloid peptide (Aβ1–42). Following the failures of clinical trials …

Nasal administration has been demonstrated as an effective alternative for drug delivery to
central nervous system (CNS), especially for use in neurodegenerative diseases. Donepezil …

Neurodegenerative disease (ND) incidence has recently increased due to improved life
expectancy. Alzheimer's (AD) or Parkinson's disease (PD) are the most prevalent NDs. Both …

Alzheimer's disease (AD) is an age-associated neurodegenerative disease. As the
population ages, the increasing prevalence of AD threatens massive healthcare costs in the …

Alzheimer's disease, a progressive neurodegenerative condition, is characterized by a
gradual decline in cognitive functions. Current treatment approaches primarily involve the …

Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by
progressive cognitive decline and memory loss, affecting millions of people worldwide …

Alzheimer's disease (AD) is the most common form of dementia. Unfortunately, despite
numerous studies, an effective treatment for AD has not yet been established. There is …

Alzheimer disease (AD) is one of the most common and disabling neuropathies in the ever-
growing aged population around the world, that especially affects Western countries. We are …